Our Work
Latham Advises Canaan and Brandon Capital on Pathios’ US$25 Million Series B
April 26, 2024
London team represents investors on funding round of leading biotech company developing therapies for cancer.
Latham & Watkins has advised Canaan and Brandon Capital as investors on the US$25 million Series B funding round of Pathios Therapeutics Limited (Pathios), a biotech company focused on the development of first-in-class therapies for cancer.
The round included participation from Canaan and Brandon Capital as existing investors, and new investment from Bristol Myers Squibb.
The Latham team was led by London corporate partner Shing Lo, with associate Toni Adejuyigbe.